{"id":"ceftazidime-avibactam-colistin-polymyxin-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (polymyxin-related)"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Phlebitis at infusion site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that inhibits bacterial peptidoglycan cross-linking; avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation. Colistin and polymyxin B are polymyxin antibiotics that bind to and disrupt bacterial lipopolysaccharide and phospholipid membranes. Together, this combination targets multidrug-resistant gram-negative pathogens including Pseudomonas aeruginosa and Acinetobacter baumannii through complementary mechanisms.","oneSentence":"This combination uses ceftazidime-avibactam to inhibit bacterial cell wall synthesis while overcoming beta-lactamase resistance, paired with colistin/polymyxin B to disrupt bacterial cell membranes, providing synergistic activity against multidrug-resistant gram-negative bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:52.944Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant gram-negative bacterial infections (including Pseudomonas aeruginosa and Acinetobacter baumannii)"},{"name":"Hospital-acquired and ventilator-associated pneumonia"},{"name":"Complicated urinary tract infections"},{"name":"Bloodstream infections"}]},"trialDetails":[{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftazidime-avibactam + Colistin/Polymyxin B","genericName":"Ceftazidime-avibactam + Colistin/Polymyxin B","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ceftazidime-avibactam to inhibit bacterial cell wall synthesis while overcoming beta-lactamase resistance, paired with colistin/polymyxin B to disrupt bacterial cell membranes, providing synergistic activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections (including Pseudomonas aeruginosa and Acinetobacter baumannii), Hospital-acquired and ventilator-associated pneumonia, Complicated urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}